TCRT - Alaunos Therapeutics Inc

https://www.alaunos.com

Momentum: Bearish

Recent News

PMGC Capital LLC, a Subsidiary of PMGC Holdings Inc. ( Nasdaq: ELAB ) , To File Schedule 13D Reporting 5.09% Stake in Alaunos Therapeutics, Inc. ( Nasdaq: TCRT ) - Alaunos Therapeutics ( NASDAQ:TCRT ) , PMGC Holdings ( NASDAQ:ELAB )

Benzinga • 4 months ago • score: 0.44

NEWPORT BEACH, Calif., May 14, 2025 ( GLOBE NEWSWIRE ) -- PMGC Capital LLC ( "PMGC Capital," "we," "our," or "us" ) , a wholly owned subsidiary of PMGC Holdings Inc. ELAB, today announced its planned filing of a Schedule 13D with the U.S.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

Alaunos Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on discovering, acquiring, developing and commercializing a portfolio of immuno-oncology therapies to treat cancer patients. The company is headquartered in Houston, Texas.

52W High

$5.48

52W Low

$1.31

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

-0.83

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-3.55

EV/Revenue (<3 favorable)

724.36

P/S (TTM) (<3 favorable)

794.06

P/B (<3 favorable)

1.17

Ownership

Retail‑heavy

Source: Overview

Insiders (1–5% typical)

14.41%

Institutions (25–75% balanced)

4.77%

Shares Outstanding

1,978,200

Float

2,091,800

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

6,000

Gross Profit (TTM)

-581,000

EPS (TTM)

-2.47

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

-672.83%

ROE (TTM) (>15% strong)

-1.08%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

1.00

Momentum

Bearish momentum

Value

-0.1141

-0.1339

Trend

Rising

Signal Cross

No cross

As of

Sep. 12, 2025